Survivors of childhood eye cancer experience normal cognitive functioning as adults

November 24, 2014

(MEMPHIS, Tenn. - November 24, 2014) Most long-term survivors of retinoblastoma, particularly those who had been diagnosed with tumors by their first birthdays, have normal cognitive function as adults, according to a St. Jude Children's Research Hospital study. The research, which appears in the current issue of the journal Cancer, found that the vast majority of survivors work full time, live independently and fulfill other milestones of adult life.

The study is the first to examine how adult survivors of retinoblastoma fare cognitively and socially decades after their diagnosis. The findings contrast with research involving survivors of other childhood cancers that suggest a younger age at cancer diagnosis may put survivors at risk for reduced cognitive functioning later in life.

"As a group, adult survivors of retinoblastoma are doing quite well based on their cognitive functioning and attainment of adult social milestones," said the study's first and corresponding author Tara Brinkman, Ph.D., an assistant member of the St. Jude Department of Epidemiology and Cancer Control and the Department of Psychology.

"This suggests that for children whose visual system is damaged very early in life, the brain may compensate by reorganizing areas responsible for processing visual information to enhance processing of verbal and auditory information," Brinkman said. "This highlights the importance of early intervention and rehabilitation for these patients."

Retinoblastoma is diagnosed in about 350 children annually in the U.S., and 95 percent of patients are younger than 5 years old when their tumor is identified. Today, more than 95 percent of retinoblastoma patients become long-term survivors. Previous research with retinoblastoma survivors focused on cognitive functioning in childhood. The results were mixed.

The 69 adult survivors in this study scored in the normal range on measures of verbal intelligence, attention, memory, executive functioning and their ability to process information. Their performance was above average for certain tasks, including non-verbal reasoning, but well below average for the fine motor dexterity needed for tasks like handwriting.

Seventy percent of survivors lived independently, and 62 percent were married or living as married couples. Fifty-eight percent had completed college. Three-quarters of survivors worked full-time, but more than half reported earning less than $20,000 annually.

Age at diagnosis was a more powerful predictor of adult cognitive functioning than whether survivors developed tumors in one or both eyes. Survivors whose retinoblastoma was identified by their first birthdays scored better on almost all measures of verbal functioning than did survivors diagnosed later. Diagnosis during the first year of life was associated with significantly better performance on tests of short- and long-term verbal memory, verbal learning and verbal intelligence.

While additional research is needed to understand the results, Brinkman and her colleagues noted that the findings are consistent with other reports that the developing central nervous system can compensate for early vision loss.

Patients diagnosed as infants are also more likely to have tumors in both eyes than children whose cancer is identified later, said co-author Rachel Brennan, M.D., an assistant member of the St. Jude Department of Oncology. "These children start rehabilitation and other interventions very early in life that stimulate sensory development and learning to compensate for possible visual impairment," she said.

Study participants were on average 33 years old and 31 years from their retinoblastoma diagnoses. All were enrolled in the St. Jude Lifetime Cohort Study (St. Jude LIFE), which brings survivors treated at St. Jude as children back to the hospital for several days of extensive testing. St. Jude LIFE is an ongoing study designed to better understand the causes and severity of the challenges facing childhood cancer survivors as they age.

Whole brain irradiation also surfaced as a risk factor for poor performance on measures of short- and long-term verbal memory, even among survivors whose overall cognitive functioning fell within the normal range. Because few survivors who developed retinoblastoma in a single eye were treated with radiation, researchers analyzed the treatment's impact on the 24 survivors who had tumors in both eyes and factored in patient age at diagnosis. Thanks to novel chemotherapy regimens and aggressive focal therapy such as laser therapy or cryotherapy, Brennan said less than 3 percent of retinoblastoma patients at St. Jude receive radiation now to save an eye.

When asked to rate their own cognitive and behavior functioning, survivors were within the normal range for most measures. But survivors were significantly more likely than U.S. adults of a similar age to report problems with working memory or in completing tasks.
The study's senior author is Kevin Krull, Ph.D., a member of the St. Jude Department of Epidemiology and Cancer Control. The other authors are Thomas Merchant, Zhenghong Li, Matthew Wilson, Mary Ellen Hoehn, Ibrahim Qaddoumi, Sean Phipps, Deokumar Srivastava, Leslie Robison and Melissa Hudson, all of St. Jude.

The research was funded in part by a grant (CA21765) from the National Cancer Institute at the National Institutes of Health and ALSAC.

St. Jude Media Relations Contacts

Carrie Strehlau
desk (901) 595-2295
cell (901) 297-9875

Summer Freeman
desk (901) 595-3061
cell (901) 297-9861

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude is working to increase the overall survival rate for childhood cancer to 90 percent in the next decade. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food--because all a family should worry about is helping their child live. To learn more, visit or follow St. Jude at @stjuderesearch.

St. Jude Children's Research Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to